Cartesian stock slips as Oppenheimer cuts despite trial win
2024-07-02
Andrii Dodonov Update 2.00PM EST: Adds latest share move and Oppenheimer’s downgrade Cell therapy developer Cartesian Therapeutics (NASDAQ:RNAC) announced Tuesday that its lead asset, Descartes-08, reached the main goal in a mid-stage trial against the muscle disorder myasthenia gravis (MG). In conjunction with the data, the Gaithersburg, Maryland-based biotech announcedContinue Reading